Co-Founder & CEO
Since Apr 2021 · 5 yrs 7 mos
Profile summary: University of Oxford Postdoctoral Research Assistant
Apoha
Apoha is a molecular science company whose Liquid Brain platform captures the sensory-like fingerprint of molecules and formulations from a sample of about 10 µg. Its VIBE check helps pharma and biotech teams screen antibodies for developability issues such as aggregation and viscosity in a single measurement.
- Drug Discovery & Therapeutics
- Biotechnology
- Data & Analytics
- Hardware
- New Materials
Updated 26 days ago
Funding
Raised to date
$36MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 2 rounds
+2- Seed
- Undisclosed
Incomplete round history. $36M of the $36M reported total isn’t matched to a known round (2 known rounds have undisclosed amounts).
RoundDateAmountValuationInvestors
Founders
Product
Problem
Machines process digital data well but cannot interpret how complex molecules physically behave, such as how they bend, ripple, dissolve, or aggregate. Characterizing the biophysical properties of biologics and formulations typically requires extensive, time-consuming analysis, which slows drug and food development.
Solution
Apoha's Liquid Brain is a liquid-state device that introduces a small sample onto an engineered liquid and captures the wave patterns generated as the two interact. These nonlinear Lucassen wave readouts form a sensory fingerprint of each molecule that reflects its underlying fluid and thermodynamic behavior. Because the readout integrates properties such as hydrophobicity, aggregation, viscosity, and thermal stability, one measurement provides a developability view that would otherwise require several separate assays. The platform maps materials by their biophysical properties and compares candidates against one another, with a current validated output that ranks antibodies and eliminates failure-prone candidates at over 90% precision. For pharma and biotech teams, a VIBE check at hit identification flags poor candidates early and requires only about 10 µg of material. Food and beverage developers can apply the same sensory-fingerprint approach to design formulations, and Apoha is developing deployable hardware to monitor protein quality during bioprocessing.
Target Audience
Primary customers are pharmaceutical and biotech researchers assessing antibody developability and formulation behavior, along with food and beverage product developers designing formulations.
Features
- Liquid-state device using nonlinear Lucassen waves to capture molecular sensory fingerprints from roughly 10 µg of material
- Single-measurement developability breakdown across hydrophobicity, conformational flexibility, surface charge, and related properties
- Plate-based workflow with fast measurement time and compatibility with PBS, histidine, and acetate buffers
- Formulation screening across pH, concentration, and buffer conditions to compare candidate behavior
- Biophysical mapping that compares molecules and predicts properties of previously untested candidates, with sequence-level prediction in development